Serial measurement of soluble interleukin 2 receptor levels: an early indicator of treatment response for Lyme disease.
Detection of antibodies produced in response to infection with Borrelia burgdorferi provides a valuable aid for diagnosing Lyme disease. However, anti-Borrelial antibody titers are of little value in determining treatment success or providing evidence of persistent infection as levels of specific antibodies can remain elevated even after successful treatment. Pretreatment and posttreatment measurement of soluble interleukin 2 receptor (sIL-2R) levels was evaluated for use in predicting treatment response in Lyme disease. Results indicate that serial measurement of serum sIL-2R levels can provide an early indicator of response to treatment and outcome.
Fawcett
P T
PT
Immunology Research Program, Alfred I. duPont Institute, Wilmington, DE 19899.
Rose
C D
CD
Proujansky
R
R
Gibney
K M
KM
Molloy
D M
DM
Doughty
R A
RA
D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000907:Antibodies, Bacterial / Q000097:blood; D015748:Borrelia burgdorferi Group / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008193:Lyme Disease / Q000188:drug therapy / Q000276:immunology*; D008213:Lymphocyte Activation; D008297:Male; D011379:Prognosis; D015375:Receptors, Interleukin-2 / Q000378:metabolism*; D012995:Solubility; D013601:T-Lymphocytes / Q000276:immunology
D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D015375:Receptors, Interleukin-2